• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Life Science Market
    Life Science News
    Life Science Stocks
    • Life Science Market
    • Life Science News
    • Life Science Stocks

    BIOLASE Wins Germany Patent Infringement Case

    Written by Investing News Network
    |
    May. 12, 2014 11:30AM PST

    BIOLASE, Inc. (NASDAQ:BIOL) received formal notice from the first instance Düsseldorf District Court that BIOLASE has won its patent infringement case, where Fotona’s Fidelis dental laser system infringes on BIOLASE’s European Patent EP 1 560 470.

    BIOLASE, Inc. (NASDAQ:BIOL) received formal notice from the first instance Düsseldorf District Court that BIOLASE has won its patent infringement case, where Fotona’s Fidelis dental laser system infringes on BIOLASE’s European Patent EP 1 560 470.

    As quoted in the press release:

    In the ruling, the Düsseldorf Court found that Fotona’s Fidelis dental laser system infringes on BIOLASE’s European Patent EP 1 560 470. BIOLASE’s European Patent EP 1 560 470 has broad claims relating to the output of optical energy of lasers; specifically, the conditions of laser-induced cutting of biological tissue where air-water spray is applied to the tissue for stimulation of mechanical cutting. The Düsseldorf Court accepted BIOLASE’s requests for injunctive relief, product recall, rendering of account, and cash damages.

    Click here to read the BIOLASE (NASDAQ:BIOL) press release

    BIOLASE, Inc. Chairman and CEO, Federico Pignatelli, said:

    This is a great victory for BIOLASE and our extensive portfolio of international patents. The Düsseldorf Court awarded BIOLASE full damages, which we estimate could amount to several million Euros for the German market alone, and injunctive relief in the critical German market which is fundamental to our European sales strategy.

    See this press release on Marketwire

    The Conversation (0)

    Go Deeper

    AI Powered
    BioMarin Pharmaceutical Inc.

    BioMarin Pharmaceutical Inc.

    BioNTech SE

    BioNTech SE

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES